A closer look at the technologies used by Crohn's MAP Vaccine
See more technologies
Crohn's MAP Vaccine
Blood & Organ Banks · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
150 Stamford Street, London, Greater Lon...Website
www.crohnsmapvaccine.comRevenue
$13.9 MillionIndustry
About Crohn's MAP Vaccine
Crohn's MAP Vaccine is focused on developing a potential cure for Crohn's disease, a severe form of Inflammatory Bowel Disease affecting millions worldwide. The company is conducting clinical trials for a therapeutic vaccine targeting Mycobacterium avium subspecies paratuberculosis (MAP), which is believed to be a contributing factor to the disease. Their services include a new diagnostic test for MAP, which aids in confirming infections prior to vaccination. The intended clients are individuals suffering from Crohn's disease, as well as healthcare professionals involved in their treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Crohn's MAP Vaccine
Compare insights from companies similar to Crohn's MAP Vaccine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Crohn's MAP Vaccine
$13.9M
51-200
Private
-
-
N/A
Crohn's MAP Vaccine Tech Stack
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Crohn's MAP Vaccine
Sign Up For FreeTo access detailed company insights
Crohn's MAP Vaccine is focused on developing a potential cure for Crohn's disease, a severe form of Inflammatory Bowel Disease affecting millions worldwide. The company is conducting clinical trials for a therapeutic vaccine targeting Mycobacterium avium subspecies paratuberculosis (MAP), which is believed to be a contributing factor to the disease... Read More
